Table 1.
Series characteristics
| n = 20 | |
|---|---|
| Age, years | 69.5 (62.0–77.7) |
| Male sex | 12 (57.1%) |
| BMI, Kg/m2 | 31.0 (21.0–36.5) |
| Charlson Comorbidity Index | 5.0 (4.0–5.0) |
| ASA | |
| II | 6 (28.6%) |
| III | 14 (66.7%) |
| Tumour | |
| Primary | 19 (95.0) |
| Recurrence | 1 (5%) |
| Distance from AV, cm | 7.5 (5.0–11.7) |
| Tumour diameter at staging, mm | 25.0 (20.0–34.0) |
| Tumour location | |
| Anterior | 2 (10.0%) |
| Antero-lateral | 3 (15.0%) |
| Posterior | 7 (35.0%) |
| Postero-lateral | 5 (25.0%) |
| Lateral | 3 (15.0%) |
| cT | |
| cTx | 2 (10.0%) |
| cT0 | 2 (10.0%) |
| cT1 | 7 (35.0%) |
| cT2 | 9 (45.0%) |
| cN0 | 20 (100.0%) |
| Previous surgery | 2 (10.0%) |
| nCRT | 2 (10.0%) |
Values are presented as number (percentage) or median (interquartile range, IQR)
ASA American Society of Anaesthesiologists’ score, AV anal verge, BMI body mass index, nCRT neoadjuvant chemoradiation